1. World Health Organization (WHO). Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016–2021: actions for impact. 2021. https://www.who.int/publications/i/item/9789240027077. Accessed March 2023.
2. Trickey A, Fraser H, Lim AG, Peacock A, Colledge S, Walker JG, et al. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol. 2019;4(6):435–44.
3. Jin F, Dore GJ, Matthews G, Luhmann N, Macdonald V, Bajis S, et al. Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(1):39–56.
4. Conway B, Truong D, Yamamoto L, Yung R, Sharma S. Use of glecaprevir/pibrentasvir (G/P) for the treatment of HCV infection among fentanyl users: an interim analysis of the GRAND PLAN study. J Hepatol. 2022;77:S553.
5. Moga T, Nallapeta N, Martinez A, editors. Variable adherence to HCV treatment among people who inject drugs treated with 8 versus 12 weeks of antiviral therapy resulted in high rates of SVR12 and reinfection rate was low. In: The Liver Meeting American Association for The Study Of Liver Disease, AASLD, 2022 Nov 4–8; Washington, DC, USA.